واکسن کووید-۱۹ فایزر–بیوان‌تک (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "واکسن کووید-۱۹ فایزر–بیوان‌تک" in Persian language version.

refsWebsite

Global rank Persian rank

81web.archive.org

1^st place

32nih.gov

4^th place

5^th place

19doi.org

2^nd place

8fda.gov

447^th place

382^nd place

6cdc.gov

218^th place

126^th place

6worldcat.org

5^th place

12^th place

6tga.gov.au

3,984^th place

1,143^rd place

6canada.ca

1,712^th place

2,923^rd place

5europa.eu

68^th place

179^th place

5gov.uk

432^nd place

1,605^th place

5reuters.com

49^th place

76^th place

4biontech.de

low place

3who.int

195^th place

129^th place

3fosunpharma.com

low place

3nytimes.com

7^th place

24^th place

3theguardian.com

12^th place

34^th place

2clinicaltrials.gov

5,225^th place

5,710^th place

2statnews.com

8,771^st place

low place

2washingtonpost.com

34^th place

90^th place

2trackvaccines.org

low place

2health.gov.au

low place

2cvdvaccine-us.com

low place

2bloomberg.com

99^th place

231^st place

2nature.com

234^th place

262^nd place

2semanticscholar.org

11^th place

52^nd place

2harvard.edu

18^th place

50^th place

1medicines.org.uk

3,823^rd place

1,188^th place

1hres.ca

low place

1admin.ch

279^th place

511^th place

1businesstech.co.za

low place

1timeslive.co.za

2,624^th place

7,643^rd place

1gov.br

5,564^th place

low place

1thestandard.com.hk

4,129^th place

low place

1npr.org

92^nd place

276^th place

1cnbc.com

220^th place

283^rd place

1abc.net.au

139^th place

355^th place

1nhs.uk

1,989^th place

650^th place

1cnn.com

28^th place

65^th place

1wsj.com

79^th place

173^rd place

1khub.net

low place

1publishing.service.gov.uk

1,877^th place

2,874^th place

1cbsnews.com

108^th place

307^th place

1thetimes.co.uk

170^th place

427^th place

1bmj.com

1,226^th place

869^th place

1nsw.gov.au

640^th place

2,589^th place

1gponline.com

low place

1mednet-communities.net

low place

1honam.ir

low place

1bbc.com

20^th place

3^rd place

1hamshahrionline.ir

851^st place

15^th place

1voanews.com

581^st place

30^th place

1dw.com

204^th place

36^th place

1healthycanadians.gc.ca

low place

abc.net.au

amp.abc.net.au

«Countries already using Pfizer coronavirus vaccine include UK, US, Canada and Singapore - ABC News». amp.abc.net.au. دریافت‌شده در ۲۰۲۱-۰۸-۲۲.

admin.ch

bag.admin.ch

"Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Archived from the original on 10 January 2021. Retrieved 19 December 2020.

bbc.com

«بریتانیا واکسن کرونای 'فایزر - بیوان تک' را برای استفاده از هفته آینده تأیید کرد». BBC News فارسی. ۲۰۲۰-۱۲-۰۲. دریافت‌شده در ۲۰۲۱-۰۹-۲۰.

biontech.de

investors.biontech.de

"Update on our COVID-19 vaccine development program with BNT162b2" (PDF) (Press release). بیوان‌تک. 2 December 2020. Archived from the original on 3 December 2020. Retrieved 12 December 2020.
"Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study". BioNTech (Press release). 1 April 2021. Archived from the original on 4 April 2021. Retrieved 11 April 2021.
"Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of Comirnaty" (Press release). BioNTech. 17 February 2021. Archived from the original on 26 February 2021. Retrieved 1 March 2021.

biontech.de

"BioNTech Covid-19" (به انگلیسی).

bloomberg.com

Kresge N (30 March 2021). "BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses". Bloomberg. Archived from the original on 11 April 2021. Retrieved 11 April 2021.
"Israel Approves Third Vaccine Dose for Those Over 50". Bloomberg. 13 August 2021. Retrieved 13 August 2021.

bmj.com

Torjesen, Ingrid (2021-05-27). "Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds". BMJ (به انگلیسی). 373: n1372. doi:10.1136/bmj.n1372. ISSN 1756-1833. PMID 34045236.

businesstech.co.za

"South Africa approves Pfizer Covid-19 vaccine for emergency use". Archived from the original on 18 March 2021. Retrieved 18 March 2021.

canada.ca

covid-vaccine.canada.ca

"Regulatory Decision Summary - Comirnaty". Health Canada. Archived from the original on 19 September 2021. Retrieved 18 September 2021.
"Comirnaty (tozinameran)". وزارت بهداشت کانادا. Archived from the original on 9 May 2022. Retrieved 31 May 2022.
"Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine". وزارت بهداشت کانادا. Archived from the original on 12 May 2021. Retrieved 11 May 2021.
"Pfizer–BioNTech COVID-19 Vaccine (tozinameran)". Health Canada. Archived from the original on 16 December 2020. Retrieved 15 December 2020.

canada.ca

"Pfizer-BioNTech Comirnaty COVID-19 vaccine". Health Canada. 9 December 2020. Archived from the original on 5 June 2021. Retrieved 18 September 2021.
"Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications". Health Canada. 17 September 2020. Archived from the original on 24 March 2021. Retrieved 17 September 2021.

cbsnews.com

Smith K (24 April 2021). "New CDC guidance recommends pregnant people get the COVID-19 vaccine". CBS News. Archived from the original on 24 April 2021. Retrieved 24 April 2021.

cdc.gov

"Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" (PDF). U.S. مرکز کنترل و پیشگیری بیماری (CDC). 28 September 2021. Archived (PDF) from the original on 2 March 2021. Retrieved 24 October 2021.
. Centers for Disease Control and Prevention (CDC). «Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older» (PDF).
CDC؛ CDC (۲۰۲۱-۰۹-۰۲). «COVID-19 Vaccination». Centers for Disease Control and Prevention (به انگلیسی). دریافت‌شده در ۲۰۲۱-۰۹-۱۹.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (2): 46–51. doi:10.15585/mmwr.mm7002e1. PMC 7808711. PMID 33444297. Archived (PDF) from the original on 24 January 2021. Retrieved 2 February 2021.
"Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines". مرکز کنترل و پیشگیری بیماری (CDC). Archived from the original on 27 June 2021. Retrieved 27 June 2021. This article incorporates text from this source, which is in the public domain.
National Center for Immunization and Respiratory Diseases (23 June 2021). "Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination". CDC.gov. Centers for Disease Control and Prevention. Archived from the original on 3 July 2021. Retrieved 2 July 2021.

clinicaltrials.gov

ClinicalTrials.gov NCT04368728 NCT04368728: Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals". ClinicalTrials.gov. 30 April 2020. Archived from the original on 11 October 2020. Retrieved 5 August 2021.

cnbc.com

Browne, Ryan (2020-11-11). "What you need to know about BioNTech — the European company behind Pfizer's Covid-19 vaccine". CNBC (به انگلیسی). Retrieved 2021-08-24.

cnn.com

Howard J (23 August 2021). "FDA grants full approval to Pfizer/BioNTech Covid-19 vaccine, opening door to more vaccine mandates". CNN. Retrieved 23 August 2021.

cvdvaccine-us.com

"Questions and Answers About Pfizer–BioNTech COVID-19 Vaccine". Pfizer. Archived from the original on 23 December 2020. Retrieved 16 December 2020.
"Pfizer–BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer-BioNTech. Archived from the original on 24 January 2021. Retrieved 17 December 2020.

doi.org

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (به انگلیسی). 596 (7872): 317–317. 2021-08-17. doi:10.1038/d41586-021-02219-w.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants". New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. PMC 8117967. PMID 33951357.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant". The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). "Vaccine Effectiveness Studies in the Field". The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021". MMWR Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. ISSN 0149-2195. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury, David S.; Cromer, Deborah; Reynaldi, Arnold; Schlub, Timothy E.; Wheatley, Adam K.; Juno, Jennifer A.; Subbarao, Kanta; Kent, Stephen J.; Triccas, James A. (2021-07). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine (به انگلیسی). 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. {{cite journal}}: Check date values in: |date= (help)
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. (April 2021). "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting". New England Journal of Medicine. 384 (15). Table 2. doi:10.1056/NEJMoa2101765. PMC 7944975. PMID 33626250.
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness". The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. eTables 6 and 7. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165.{{cite journal}}: نگهداری CS1: موقعیت (link)
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (April 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". N Engl J Med. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
Torjesen, Ingrid (2021-05-27). "Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds". BMJ (به انگلیسی). 373: n1372. doi:10.1136/bmj.n1372. ISSN 1756-1833. PMID 34045236.
Klein, Nicola P.; Lewis, Ned; Goddard, Kristin; Fireman, Bruce; Zerbo, Ousseny; Hanson, Kayla E.; Donahue, James G.; Kharbanda, Elyse O.; Naleway, Allison; Nelson, Jennifer Clark; Xu, Stan; Yih, W. Katherine; Glanz, Jason M.; Williams, Joshua T. B.; Hambidge, Simon J.; Lewin, Bruno J.; Shimabukuro, Tom T.; DeStefano, Frank; Weintraub, Eric S. (3 September 2021). "Surveillance for Adverse Events After COVID-19 mRNA Vaccination". JAMA. doi:10.1001/jama.2021.15072. PMID 34477808.
Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A (June 2021). "Adverse reactions to COVID-19 vaccines: A practical approach". Clinical and Experimental Allergy. 51 (6): 770–777. doi:10.1111/cea.13880. PMC 8250847. PMID 33813758.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (2): 46–51. doi:10.15585/mmwr.mm7002e1. PMC 7808711. PMID 33444297. Archived (PDF) from the original on 24 January 2021. Retrieved 2 February 2021.
Cabanillas B, Akdis CA, Novak N (June 2021). "Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?". Allergy. 76 (6): 1617–1618. doi:10.1111/all.14711. PMID 33320974. S2CID 229284320.
Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. (April 2021). "BNT162b vaccines protect rhesus macaques from SARS-CoV-2". Nature. 592 (7853): 283–289. Bibcode:2021Natur.592..283V. doi:10.1038/s41586-021-03275-y. PMID 33524990.
Gaebler C, Nussenzweig MC (October 2020). "All eyes on a hurdle race for a SARS-CoV-2 vaccine". Nature. 586 (7830): 501–2. Bibcode:2020Natur.586..501G. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

dw.com

Welle (www.dw.com)، Deutsche. «واکسن کرونای بیون‌تک - فایزر در آمریکا پروانه دریافت کرد | DW | 12.12.2020». DW.COM. دریافت‌شده در ۲۰۲۰-۱۲-۳۰.

europa.eu

ema.europa.eu

"Comirnaty EPAR". آژانس دارویی اروپا (EMA). Archived from the original on 17 March 2021. Retrieved 23 December 2020.
"First COVID-19 vaccine approved for children aged 12 to 15 in EU". آژانس دارویی اروپا (EMA) (Press release). 28 May 2021. Archived from the original on 28 May 2021. Retrieved 29 May 2021.
Comirnaty: Product Information (PDF) (Report). آژانس دارویی اروپا (EMA). Retrieved 23 December 2020.
"COVID-19 vaccine safety update: Comirnaty" (PDF). آژانس دارویی اروپا (EMA). 28 January 2021. Archived (PDF) from the original on 2 June 2021. Retrieved 30 January 2021.
"COVID-19 vaccine safety update: COMIRNATY: BioNTech Manufacturing GmbH" (PDF). Europa. 14 April 2021. Archived (PDF) from the original on 2 June 2021. Retrieved 16 April 2021.

fda.gov

"Comirnaty". U.S. سازمان غذا و دارو (آمریکا) (FDA). 23 August 2021. STN: 125742. Retrieved 23 August 2021.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age". U.S. سازمان غذا و دارو (آمریکا) (FDA) (Press release). 17 June 2022. Archived from the original on 17 June 2022. Retrieved 17 June 2022.
"FDA Approves First COVID-19 Vaccine" (Press release). U.S. سازمان غذا و دارو (آمریکا) (FDA). 23 August 2021. Archived from the original on 23 August 2021. Retrieved 23 August 2021.
"Pfizer–BioNTech COVID-19 Vaccine EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 12 August 2021. Archived from the original on 14 August 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
"Pfizer–BioNTech COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA). 3 February 2021. Archived from the original on 14 January 2021. Retrieved 5 February 2021.
"Pfizer–BioNTech COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA). 3 February 2021. Archived from the original on 14 January 2021. Retrieved 5 February 2021.
Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum (PDF). U.S. سازمان غذا و دارو (آمریکا) (FDA) (Report). 14 December 2020. Archived from the original on 29 January 2021. Retrieved 14 December 2020. This article incorporates text from this source, which is in the public domain.
Commissioner, Office of the (2021-08-16). "Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals". FDA (به انگلیسی). Retrieved 2021-09-19.

fosunpharma.com

"Fosun Pharma and BioNTech form COVID-19 vaccine strategic alliance in China" (Press release). Fosun Pharma. 15 March 2020. Archived from the original on 15 August 2020. Retrieved 20 March 2021.
"BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine" (Press release). Fosun Pharma. 16 December 2020. Archived from the original on 18 April 2021. Retrieved 2021-04-18.
"BioNTech and Fosun Pharma Jointly Announce the Arrival of the First Batch of COVID-19 mRNA Vaccine in Hong Kong and Macau" (Press release). داروسازی فوسان. 27 February 2021. Archived from the original on 15 April 2021. Retrieved 15 April 2021.

gov.br

"Anvisa concede primeiro registro definitivo para vacina contra a Covid-19 nas Américas" [Anvisa grants first definitive registration for Covid-19 vaccine in the Americas] (به پرتغالی). Federal government of Brazil. 23 February 2021. Archived from the original on 20 November 2021. Retrieved 20 November 2021.

gov.uk

"Regulatory approval of Pfizer/BioNTech vaccine for COVID-19". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 27 September 2021. Archived from the original on 19 January 2021. Retrieved 24 October 2021.
"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 10 December 2020. Retrieved 21 December 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 31 December 2020. Archived from the original on 26 February 2021. Retrieved 8 January 2021.
"Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 8 December 2020. Archived from the original on 30 May 2021. Retrieved 29 May 2021.
"UK medicines regulator gives approval for first UK COVID-19 vaccine" (Press release). آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.

gponline.com

Bostock N (9 December 2020). "MHRA warning after allergic reactions in NHS staff given COVID-19 vaccine". GP. Archived from the original on 9 December 2020. Retrieved 9 December 2020.

hamshahrionline.ir

«کانادا واکسن کرونای فایزر را تأیید کرد| واکسیناسیون از هفته آینده شروع می‌شود». همشهری آنلاین. ۲۰۲۰-۱۲-۰۹. دریافت‌شده در ۲۰۲۰-۱۲-۳۰.

harvard.edu

ui.adsabs.harvard.edu

Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. (April 2021). "BNT162b vaccines protect rhesus macaques from SARS-CoV-2". Nature. 592 (7853): 283–289. Bibcode:2021Natur.592..283V. doi:10.1038/s41586-021-03275-y. PMID 33524990.
Gaebler C, Nussenzweig MC (October 2020). "All eyes on a hurdle race for a SARS-CoV-2 vaccine". Nature. 586 (7830): 501–2. Bibcode:2020Natur.586..501G. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

health.gov.au

Australian Government Department of Health (2021-01-24). "About the Pfizer/BioNTech COVID-19 vaccine". Australian Government Department of Health (به انگلیسی). Archived from the original on 23 May 2021. Retrieved 2021-05-31.
Australian Government Department of Health (24 January 2021). "About the Pfizer/BioNTech COVID-19 vaccine". Australian Government Department of Health (به انگلیسی). Archived from the original on 23 May 2021. Retrieved 31 May 2021.

healthycanadians.gc.ca

"Pfizer–BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies". وزارت بهداشت کانادا. 12 December 2020. Archived from the original on 22 December 2020. Retrieved 21 December 2020.

honam.ir

«شرکت فایزر و BioNTech، نزدیک‌تر از همیشه به واکسن کرونا! | شتابدهنده هنام». هنام | پایگاه خبری تحلیلی دارو و سلامت. ۲۰۲۰-۱۰-۱۴. بایگانی‌شده از اصلی در ۷ مارس ۲۰۲۱. دریافت‌شده در ۲۰۲۱-۰۹-۲۰.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Comirnaty". وزارت بهداشت کانادا. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

khub.net

Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. (14 June 2021). Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant (نسخه پیش از انتشار). Public Health England. Table 1. Archived from the original on 23 June 2021. Retrieved 25 June 2021 – via Knowledge Hub.

medicines.org.uk

"Comirnaty 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 4 February 2022. Retrieved 4 February 2022.

mednet-communities.net

World Health Organization (September 2020). "Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein". WHO MedNet. Archived from the original (DOC) on 5 January 2021. Retrieved 16 December 2020.

nature.com

"The WHO is right to call a temporary halt to COVID vaccine boosters". Nature (به انگلیسی). 596 (7872): 317–317. 2021-08-17. doi:10.1038/d41586-021-02219-w.
Khoury, David S.; Cromer, Deborah; Reynaldi, Arnold; Schlub, Timothy E.; Wheatley, Adam K.; Juno, Jennifer A.; Subbarao, Kanta; Kent, Stephen J.; Triccas, James A. (2021-07). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine (به انگلیسی). 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. {{cite journal}}: Check date values in: |date= (help)

nhs.uk

"Coronavirus vaccine". National Health Service. 7 December 2020. Archived from the original on 7 December 2020. Retrieved 7 December 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants". New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. PMC 8117967. PMID 33951357.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant". The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). "Vaccine Effectiveness Studies in the Field". The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021". MMWR Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. ISSN 0149-2195. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. (April 2021). "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting". New England Journal of Medicine. 384 (15). Table 2. doi:10.1056/NEJMoa2101765. PMC 7944975. PMID 33626250.
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness". The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. eTables 6 and 7. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165.{{cite journal}}: نگهداری CS1: موقعیت (link)
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (April 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". N Engl J Med. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
Torjesen, Ingrid (2021-05-27). "Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds". BMJ (به انگلیسی). 373: n1372. doi:10.1136/bmj.n1372. ISSN 1756-1833. PMID 34045236.
Klein, Nicola P.; Lewis, Ned; Goddard, Kristin; Fireman, Bruce; Zerbo, Ousseny; Hanson, Kayla E.; Donahue, James G.; Kharbanda, Elyse O.; Naleway, Allison; Nelson, Jennifer Clark; Xu, Stan; Yih, W. Katherine; Glanz, Jason M.; Williams, Joshua T. B.; Hambidge, Simon J.; Lewin, Bruno J.; Shimabukuro, Tom T.; DeStefano, Frank; Weintraub, Eric S. (3 September 2021). "Surveillance for Adverse Events After COVID-19 mRNA Vaccination". JAMA. doi:10.1001/jama.2021.15072. PMID 34477808.
Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A (June 2021). "Adverse reactions to COVID-19 vaccines: A practical approach". Clinical and Experimental Allergy. 51 (6): 770–777. doi:10.1111/cea.13880. PMC 8250847. PMID 33813758.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (2): 46–51. doi:10.15585/mmwr.mm7002e1. PMC 7808711. PMID 33444297. Archived (PDF) from the original on 24 January 2021. Retrieved 2 February 2021.
Cabanillas B, Akdis CA, Novak N (June 2021). "Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?". Allergy. 76 (6): 1617–1618. doi:10.1111/all.14711. PMID 33320974. S2CID 229284320.
Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. (April 2021). "BNT162b vaccines protect rhesus macaques from SARS-CoV-2". Nature. 592 (7853): 283–289. Bibcode:2021Natur.592..283V. doi:10.1038/s41586-021-03275-y. PMID 33524990.
Gaebler C, Nussenzweig MC (October 2020). "All eyes on a hurdle race for a SARS-CoV-2 vaccine". Nature. 586 (7830): 501–2. Bibcode:2020Natur.586..501G. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

ncbi.nlm.nih.gov

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants". New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. PMC 8117967. PMID 33951357.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant". The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). "Vaccine Effectiveness Studies in the Field". The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021". MMWR Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. ISSN 0149-2195. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. (April 2021). "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting". New England Journal of Medicine. 384 (15). Table 2. doi:10.1056/NEJMoa2101765. PMC 7944975. PMID 33626250.
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness". The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). "Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study". BMJ. eTables 6 and 7. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165.{{cite journal}}: نگهداری CS1: موقعیت (link)
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. (April 2021). "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons". N Engl J Med. 384 (24): 2273–2282. doi:10.1056/NEJMoa2104983. PMC 8117969. PMID 33882218.
Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A (June 2021). "Adverse reactions to COVID-19 vaccines: A practical approach". Clinical and Experimental Allergy. 51 (6): 770–777. doi:10.1111/cea.13880. PMC 8250847. PMID 33813758.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (2): 46–51. doi:10.15585/mmwr.mm7002e1. PMC 7808711. PMID 33444297. Archived (PDF) from the original on 24 January 2021. Retrieved 2 February 2021.

dailymed.nlm.nih.gov

"Pfizer-Biontech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 16 November 2020. Retrieved 24 October 2021.
"Pfizer-BioNTech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 21 October 2021. Retrieved 24 October 2021.
"Comirnaty- covid-19 vaccine, mrna injection, suspension". DailyMed. Archived from the original on 4 February 2022. Retrieved 4 February 2022.

npr.org

"Pfizer says experimental COVID-19 vaccine is more than 90% effective". NPR. 9 November 2020. Archived from the original on 9 November 2020. Retrieved 9 November 2020.

nsw.gov.au

aci.health.nsw.gov.au

"Immunocompromised patients and COVID-19 vaccines" (PDF). NSW Health. 28 April 2021. Archived (PDF) from the original on 20 May 2021. Retrieved 2 June 2021.

nytimes.com

Thomas K (20 November 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". نیویورک تایمز. Archived from the original on 12 December 2020.
«Covid World Vaccination Tracker - The New York Times». web.archive.org. ۲۰۲۱-۰۸-۲۴. بایگانی‌شده از اصلی در ۲۴ اوت ۲۰۲۱. دریافت‌شده در ۲۰۲۱-۰۸-۲۴.
Thomas K (20 November 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". نیویورک تایمز. Archived from the original on 12 December 2020.

publishing.service.gov.uk

assets.publishing.service.gov.uk

SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 17 (PDF) (Briefing). Public Health England. 25 June 2021. GOV-8576. Archived (PDF) from the original on 25 June 2021. Retrieved 26 June 2021.

reuters.com

"Brazil approves Pfizer's COVID-19 shot, but has none to use". Reuters. 23 February 2021. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
Burger L (15 March 2020). "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Archived from the original on 14 November 2020. Retrieved 10 November 2020.
Burger, Ludwig (16 March 2020). "BioNTech in China alliance with Fosun over potential coronavirus vaccine". Reuters. Archived from the original on 14 April 2021. Retrieved 19 March 2021. BioNTech struck a collaboration deal with Shanghai Fosun Pharmaceutical over the German biotech firm's rights in China to an experimental coronavirus vaccine, the latest gambit in a global race to halt the pandemic.
"BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China". Reuters. 25 November 2020. Archived from the original on 14 April 2021. Retrieved 20 March 2021. BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.
Heller J (2 June 2021). "Israel sees probable link between Pfizer vaccine and myocarditis cases". Reuters. Archived from the original on 25 June 2021. Retrieved 3 June 2021.

semanticscholar.org

api.semanticscholar.org

Cabanillas B, Akdis CA, Novak N (June 2021). "Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?". Allergy. 76 (6): 1617–1618. doi:10.1111/all.14711. PMID 33320974. S2CID 229284320.
Gaebler C, Nussenzweig MC (October 2020). "All eyes on a hurdle race for a SARS-CoV-2 vaccine". Nature. 586 (7830): 501–2. Bibcode:2020Natur.586..501G. doi:10.1038/d41586-020-02926-w. PMID 33077943. S2CID 224808629.

statnews.com

"Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". STAT. 9 November 2020. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
Herper M (9 November 2020). "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". Stat News. Archived from the original on 9 November 2020. Retrieved 9 November 2020.

tga.gov.au

"Comirnaty". Therapeutic Goods Administration (TGA). 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
"AusPAR: Tozinameran". Therapeutic Goods Administration (TGA). 8 February 2022. Archived from the original on 24 March 2022. Retrieved 24 March 2022.
"COVID-19 vaccine: Pfizer Australia - Comirnaty BNT162b2 (mRNA) - approved for use in individuals 12 years and older". Therapeutic Goods Administration (TGA). 27 August 2021. Archived from the original on 23 July 2021. Retrieved 22 October 2021.
"TGA Provisional Approval of Pfizer-BioNTech COVID-19 vaccine to include 12-15 years age group". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 22 October 2021. Retrieved 22 October 2021.
"AusPAR: Tozinameran (mRNA Covid 19 vaccine)". Therapeutic Goods Administration (TGA). 13 December 2021. Archived from the original on 23 March 2022. Retrieved 23 March 2022.

ebs.tga.gov.au

"Comirnaty (BNT162b2 [mRNA]) COVID-19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.

theguardian.com

Boseley S, Halliday J (2 December 2020). "UK approves Pfizer/BioNTech Covid vaccine for rollout next week". گاردین. Archived from the original on 2 December 2020. Retrieved 14 December 2020.
"Pfizer vaccine second dose has 'sweet spot' after eight weeks, UK scientists say". 23 July 2021. Retrieved 26 July 2021.
"UK regulator approves Pfizer Covid vaccine for 12- to 15-year-olds". گاردین. 4 June 2021. Archived from the original on 4 June 2021. Retrieved 4 June 2021.

thestandard.com.hk

"BioNTech and China partner, not Pfizer, to produce HK shots". The Standard. 14 December 2020. Archived from the original on 18 April 2021. Retrieved 18 April 2021.

thetimes.co.uk

Reynolds J. "Pfizer vaccine approved for use in children aged 12 to 15 in the UK". تایمز. ISSN 0140-0460. Archived from the original on 4 June 2021. Retrieved 4 June 2021.

timeslive.co.za

Nkanjeni U. "Pfizer-BioNTec approved for emergency use in SA: here is what you need to know about the vaccine". TimesLIVE. Archived from the original on 19 April 2021. Retrieved 19 March 2021.

trackvaccines.org

covid19.trackvaccines.org

"COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2". دانشگاه مک‌گیل. Archived from the original on 8 May 2021. Retrieved 8 May 2021.
"COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2". دانشگاه مک‌گیل. Archived from the original on 8 May 2021. Retrieved 8 May 2021.

voanews.com

ir.voanews.com

«ورود محموله‌های منجمد واکسن کووید۱۹ فایزر به کشورهای اتحادیه اروپا | صدای آمریکا فارسی». ir.voanews.com. دریافت‌شده در ۲۰۲۰-۱۲-۳۰.

washingtonpost.com

«Inside Pfizer's race to produce the world's biggest supply of covid vaccine».
Booth W, Cunningham E (9 December 2020). "Britain warns against Pfizer vaccine for people with history of 'significant' allergic reactions". واشنگتن پست. Archived from the original on 9 December 2020. Retrieved 9 December 2020.

web.archive.org

"Comirnaty 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"Comirnaty EPAR". آژانس دارویی اروپا (EMA). Archived from the original on 17 March 2021. Retrieved 23 December 2020.
"Comirnaty". Therapeutic Goods Administration (TGA). 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
"Comirnaty (BNT162b2 [mRNA]) COVID-19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.
"AusPAR: Tozinameran". Therapeutic Goods Administration (TGA). 8 February 2022. Archived from the original on 24 March 2022. Retrieved 24 March 2022.
"COVID-19 vaccine: Pfizer Australia - Comirnaty BNT162b2 (mRNA) - approved for use in individuals 12 years and older". Therapeutic Goods Administration (TGA). 27 August 2021. Archived from the original on 23 July 2021. Retrieved 22 October 2021.
"TGA Provisional Approval of Pfizer-BioNTech COVID-19 vaccine to include 12-15 years age group". Therapeutic Goods Administration (TGA). 23 July 2021. Archived from the original on 22 October 2021. Retrieved 22 October 2021.
"AusPAR: Tozinameran (mRNA Covid 19 vaccine)". Therapeutic Goods Administration (TGA). 13 December 2021. Archived from the original on 23 March 2022. Retrieved 23 March 2022.
"Regulatory Decision Summary - Comirnaty". Health Canada. Archived from the original on 19 September 2021. Retrieved 18 September 2021.
"Pfizer-BioNTech Comirnaty COVID-19 vaccine". Health Canada. 9 December 2020. Archived from the original on 5 June 2021. Retrieved 18 September 2021.
"Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications". Health Canada. 17 September 2020. Archived from the original on 24 March 2021. Retrieved 17 September 2021.
"Summary Basis of Decision (SBD) for Comirnaty". وزارت بهداشت کانادا. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Comirnaty (tozinameran)". وزارت بهداشت کانادا. Archived from the original on 9 May 2022. Retrieved 31 May 2022.
"Regulatory approval of Pfizer/BioNTech vaccine for COVID-19". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 27 September 2021. Archived from the original on 19 January 2021. Retrieved 24 October 2021.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 31 December 2020. Archived from the original on 26 February 2021. Retrieved 8 January 2021.
"Pfizer-Biontech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 16 November 2020. Retrieved 24 October 2021.
"Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age". U.S. سازمان غذا و دارو (آمریکا) (FDA) (Press release). 17 June 2022. Archived from the original on 17 June 2022. Retrieved 17 June 2022.
"FDA Approves First COVID-19 Vaccine" (Press release). U.S. سازمان غذا و دارو (آمریکا) (FDA). 23 August 2021. Archived from the original on 23 August 2021. Retrieved 23 August 2021.
"Pfizer–BioNTech COVID-19 Vaccine EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 12 August 2021. Archived from the original on 14 August 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
"Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" (PDF). U.S. مرکز کنترل و پیشگیری بیماری (CDC). 28 September 2021. Archived (PDF) from the original on 2 March 2021. Retrieved 24 October 2021.
"Pfizer-BioNTech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 21 October 2021. Retrieved 24 October 2021.
"Comirnaty- covid-19 vaccine, mrna injection, suspension". DailyMed. Archived from the original on 4 February 2022. Retrieved 4 February 2022.
"Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Archived from the original on 10 January 2021. Retrieved 19 December 2020.
"South Africa approves Pfizer Covid-19 vaccine for emergency use". Archived from the original on 18 March 2021. Retrieved 18 March 2021.
Nkanjeni U. "Pfizer-BioNTec approved for emergency use in SA: here is what you need to know about the vaccine". TimesLIVE. Archived from the original on 19 April 2021. Retrieved 19 March 2021.
"Brazil approves Pfizer's COVID-19 shot, but has none to use". Reuters. 23 February 2021. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
"Anvisa concede primeiro registro definitivo para vacina contra a Covid-19 nas Américas" [Anvisa grants first definitive registration for Covid-19 vaccine in the Americas] (به پرتغالی). Federal government of Brazil. 23 February 2021. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
World Health Organization (2020). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)" (PDF). WHO Drug Information. 34 (3): 666. Archived from the original (PDF) on 27 November 2020. Retrieved 23 November 2020.
Burger L (15 March 2020). "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Archived from the original on 14 November 2020. Retrieved 10 November 2020.
"Fosun Pharma and BioNTech form COVID-19 vaccine strategic alliance in China" (Press release). Fosun Pharma. 15 March 2020. Archived from the original on 15 August 2020. Retrieved 20 March 2021.
"BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine" (Press release). Fosun Pharma. 16 December 2020. Archived from the original on 18 April 2021. Retrieved 2021-04-18.
Burger, Ludwig (16 March 2020). "BioNTech in China alliance with Fosun over potential coronavirus vaccine". Reuters. Archived from the original on 14 April 2021. Retrieved 19 March 2021. BioNTech struck a collaboration deal with Shanghai Fosun Pharmaceutical over the German biotech firm's rights in China to an experimental coronavirus vaccine, the latest gambit in a global race to halt the pandemic.
"BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China". Reuters. 25 November 2020. Archived from the original on 14 April 2021. Retrieved 20 March 2021. BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.
"BioNTech and Fosun Pharma Jointly Announce the Arrival of the First Batch of COVID-19 mRNA Vaccine in Hong Kong and Macau" (Press release). داروسازی فوسان. 27 February 2021. Archived from the original on 15 April 2021. Retrieved 15 April 2021.
"BioNTech and China partner, not Pfizer, to produce HK shots". The Standard. 14 December 2020. Archived from the original on 18 April 2021. Retrieved 18 April 2021.
"Pfizer says experimental COVID-19 vaccine is more than 90% effective". NPR. 9 November 2020. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
"Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". STAT. 9 November 2020. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
"Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine". وزارت بهداشت کانادا. Archived from the original on 12 May 2021. Retrieved 11 May 2021.
"First COVID-19 vaccine approved for children aged 12 to 15 in EU". آژانس دارویی اروپا (EMA) (Press release). 28 May 2021. Archived from the original on 28 May 2021. Retrieved 29 May 2021.
"Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine". آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 8 December 2020. Archived from the original on 30 May 2021. Retrieved 29 May 2021.
"Pfizer–BioNTech COVID-19 Vaccine (tozinameran)". Health Canada. Archived from the original on 16 December 2020. Retrieved 15 December 2020.
"COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2". دانشگاه مک‌گیل. Archived from the original on 8 May 2021. Retrieved 8 May 2021.
"Pfizer–BioNTech COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA). 3 February 2021. Archived from the original on 14 January 2021. Retrieved 5 February 2021.
Thomas K (20 November 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". نیویورک تایمز. Archived from the original on 12 December 2020.
Australian Government Department of Health (2021-01-24). "About the Pfizer/BioNTech COVID-19 vaccine". Australian Government Department of Health (به انگلیسی). Archived from the original on 23 May 2021. Retrieved 2021-05-31.
«Covid World Vaccination Tracker - The New York Times». web.archive.org. ۲۰۲۱-۰۸-۲۴. بایگانی‌شده از اصلی در ۲۴ اوت ۲۰۲۱. دریافت‌شده در ۲۰۲۱-۰۸-۲۴.
"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals". ClinicalTrials.gov. 30 April 2020. Archived from the original on 11 October 2020. Retrieved 5 August 2021.
"Update on our COVID-19 vaccine development program with BNT162b2" (PDF) (Press release). بیوان‌تک. 2 December 2020. Archived from the original on 3 December 2020. Retrieved 12 December 2020.
Herper M (9 November 2020). "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". Stat News. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
"Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study". BioNTech (Press release). 1 April 2021. Archived from the original on 4 April 2021. Retrieved 11 April 2021.
"Questions and Answers About Pfizer–BioNTech COVID-19 Vaccine". Pfizer. Archived from the original on 23 December 2020. Retrieved 16 December 2020.
"Coronavirus vaccine". National Health Service. 7 December 2020. Archived from the original on 7 December 2020. Retrieved 7 December 2020.
"UK medicines regulator gives approval for first UK COVID-19 vaccine" (Press release). آژانس نظارتی داروها و محصولات بهداشتی (بریتانیا) (MHRA). 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
Boseley S, Halliday J (2 December 2020). "UK approves Pfizer/BioNTech Covid vaccine for rollout next week". گاردین. Archived from the original on 2 December 2020. Retrieved 14 December 2020.
"COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2". دانشگاه مک‌گیل. Archived from the original on 8 May 2021. Retrieved 8 May 2021.
"Pfizer–BioNTech COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA). 3 February 2021. Archived from the original on 14 January 2021. Retrieved 5 February 2021.
Thomas K (20 November 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". نیویورک تایمز. Archived from the original on 12 December 2020.
Australian Government Department of Health (24 January 2021). "About the Pfizer/BioNTech COVID-19 vaccine". Australian Government Department of Health (به انگلیسی). Archived from the original on 23 May 2021. Retrieved 31 May 2021.
"Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of Comirnaty" (Press release). BioNTech. 17 February 2021. Archived from the original on 26 February 2021. Retrieved 1 March 2021.
Kresge N (30 March 2021). "BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses". Bloomberg. Archived from the original on 11 April 2021. Retrieved 11 April 2021.
"Pfizer–BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer-BioNTech. Archived from the original on 24 January 2021. Retrieved 17 December 2020.
Hopkins JS (30 March 2021). "Pfizer to Test Covid-19 Vaccine That Doesn't Need Ultracold Storage". The Wall Street Journal. Archived from the original on 15 May 2021. Retrieved 16 May 2021.
Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum (PDF). U.S. سازمان غذا و دارو (آمریکا) (FDA) (Report). 14 December 2020. Archived from the original on 29 January 2021. Retrieved 14 December 2020. This article incorporates text from this source, which is in the public domain.
Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing (Guidance). World Health Organization. 15 June 2021. WHO/2019-nCoV/vaccines/SAGE_recommendation//BNT162b2/2021.2. Archived from the original on 29 June 2021. Retrieved 3 July 2021.
Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. (14 June 2021). Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant (نسخه پیش از انتشار). Public Health England. Table 1. Archived from the original on 23 June 2021. Retrieved 25 June 2021 – via Knowledge Hub.
SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 17 (PDF) (Briefing). Public Health England. 25 June 2021. GOV-8576. Archived (PDF) from the original on 25 June 2021. Retrieved 26 June 2021.
Smith K (24 April 2021). "New CDC guidance recommends pregnant people get the COVID-19 vaccine". CBS News. Archived from the original on 24 April 2021. Retrieved 24 April 2021.
"UK regulator approves Pfizer Covid vaccine for 12- to 15-year-olds". گاردین. 4 June 2021. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
Reynolds J. "Pfizer vaccine approved for use in children aged 12 to 15 in the UK". تایمز. ISSN 0140-0460. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
"Immunocompromised patients and COVID-19 vaccines" (PDF). NSW Health. 28 April 2021. Archived (PDF) from the original on 20 May 2021. Retrieved 2 June 2021.
CDC COVID-19 Response Team (January 2021). "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (2): 46–51. doi:10.15585/mmwr.mm7002e1. PMC 7808711. PMID 33444297. Archived (PDF) from the original on 24 January 2021. Retrieved 2 February 2021.
"COVID-19 vaccine safety update: Comirnaty" (PDF). آژانس دارویی اروپا (EMA). 28 January 2021. Archived (PDF) from the original on 2 June 2021. Retrieved 30 January 2021.
Bostock N (9 December 2020). "MHRA warning after allergic reactions in NHS staff given COVID-19 vaccine". GP. Archived from the original on 9 December 2020. Retrieved 9 December 2020.
Booth W, Cunningham E (9 December 2020). "Britain warns against Pfizer vaccine for people with history of 'significant' allergic reactions". واشنگتن پست. Archived from the original on 9 December 2020. Retrieved 9 December 2020.
"COVID-19 vaccine safety update: COMIRNATY: BioNTech Manufacturing GmbH" (PDF). Europa. 14 April 2021. Archived (PDF) from the original on 2 June 2021. Retrieved 16 April 2021.
Heller J (2 June 2021). "Israel sees probable link between Pfizer vaccine and myocarditis cases". Reuters. Archived from the original on 25 June 2021. Retrieved 3 June 2021.
"Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines". مرکز کنترل و پیشگیری بیماری (CDC). Archived from the original on 27 June 2021. Retrieved 27 June 2021. This article incorporates text from this source, which is in the public domain.
National Center for Immunization and Respiratory Diseases (23 June 2021). "Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination". CDC.gov. Centers for Disease Control and Prevention. Archived from the original on 3 July 2021. Retrieved 2 July 2021.
World Health Organization (September 2020). "Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein". WHO MedNet. Archived from the original (DOC) on 5 January 2021. Retrieved 16 December 2020.
«شرکت فایزر و BioNTech، نزدیک‌تر از همیشه به واکسن کرونا! | شتابدهنده هنام». هنام | پایگاه خبری تحلیلی دارو و سلامت. ۲۰۲۰-۱۰-۱۴. بایگانی‌شده از اصلی در ۷ مارس ۲۰۲۱. دریافت‌شده در ۲۰۲۱-۰۹-۲۰.
"Pfizer–BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies". وزارت بهداشت کانادا. 12 December 2020. Archived from the original on 22 December 2020. Retrieved 21 December 2020.

who.int

World Health Organization (2020). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)" (PDF). WHO Drug Information. 34 (3): 666. Archived from the original (PDF) on 27 November 2020. Retrieved 23 November 2020.
Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing (Guidance). World Health Organization. 15 June 2021. WHO/2019-nCoV/vaccines/SAGE_recommendation//BNT162b2/2021.2. Archived from the original on 29 June 2021. Retrieved 3 July 2021.
"Interim statement on COVID-19 vaccine booster doses". www.who.int (به انگلیسی). Retrieved 2021-09-19.

worldcat.org

Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021". MMWR Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. ISSN 0149-2195. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury, David S.; Cromer, Deborah; Reynaldi, Arnold; Schlub, Timothy E.; Wheatley, Adam K.; Juno, Jennifer A.; Subbarao, Kanta; Kent, Stephen J.; Triccas, James A. (2021-07). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine (به انگلیسی). 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. {{cite journal}}: Check date values in: |date= (help)
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness". The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Reynolds J. "Pfizer vaccine approved for use in children aged 12 to 15 in the UK". تایمز. ISSN 0140-0460. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
Torjesen, Ingrid (2021-05-27). "Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds". BMJ (به انگلیسی). 373: n1372. doi:10.1136/bmj.n1372. ISSN 1756-1833. PMID 34045236.

wsj.com

Hopkins JS (30 March 2021). "Pfizer to Test Covid-19 Vaccine That Doesn't Need Ultracold Storage". The Wall Street Journal. Archived from the original on 15 May 2021. Retrieved 16 May 2021.